A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
A new clinical trial has shown promising results for a personalized mRNA vaccine combined with immunotherapy in preventing melanoma recurrence. The study found that 68.8% of patients receiving the combination therapy remained cancer-free after five years, compared to 49.1% for those on immunotherapy alone. This approach tailors the vaccine to each patient's tumor, potentially improving outcomes for high-risk melanoma patients.
- ▪Connie Franciosi participated in a trial testing a personalized mRNA vaccine for melanoma.
- ▪The trial included 157 patients and showed a 49% reduction in the risk of cancer recurrence with the combination therapy.
- ▪Dr. Janice Mehnert highlighted the unique approach of using personalized immunotherapy to optimize patient outcomes.
NPR — News files mainly under news. We currently carry 541 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | NPR Topics: News |
| Canonical URL | https://www.npr.org/2026/06/01/nx-s1-5827041/cancer-vaccine-mrna-melanoma |
| Publication time | Mon, 01 Jun 2026 08:00:00 -0400 |
| Retrieval time | 2026-06-01T14:01:57.923Z |
| Last seen | 2026-06-01T14:01:57.923Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 7HoEnwmRqsM3 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health A cancer vaccine made just for you. mRNA is back and it's fighting melanoma June 1, 20268:00 AM ET Allison Aubrey Connie Franciosi, 80, was part of a trial that looked at using an mRNA vaccine and an immunotherapy drug to prevent the recurrence of melanoma. Lynn Winkler hide caption toggle caption Lynn Winkler Connie Franciosi, 80, noticed a suspicious spot on her skin and was diagnosed with melanoma in 2020. "It was considered a late diagnosis," she says. The skin cancer can be difficult to treat if it's not detected and treated early, and it can spread to other parts of the body. There are approximately 112,000 melanomas diagnosed in the U.S. each year and about 8,500 deaths.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at NPR Topics: News.
Discussion
0 commentsMore from NPR Topics: News
